FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Pharma & Biotech
Pharma & Biotech
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
Pharma & Biotech
Can Lunai Bioworks Inc.’s BBB delivery platform unlock scalable Alzheimer’s drug development advantages?
Can Lunai Bioworks Inc. overcome the blood brain barrier in Alzheimer’s treatment? Discover what this $20M deal changes for CNS drug development.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Medical Devices & Diagnostics
C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence
C2N's eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer's patient selection. Read the analysis.
Medical Devices & Diagnostics
Lucent Diagnostics expands cognitive biomarker reach through Life Line Screening
Lucent Diagnostics partners with Life Line Screening to expand Alzheimer’s blood testing nationwide. Discover what this means for early detection.
Medical Devices & Diagnostics
Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?
Find out how Fujirebio’s new Lumipulse pTau 217 CSF assay could shape the future of Alzheimer’s biomarker research and platform-based diagnostics.
Pharma & Biotech
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.
Pharma & Biotech
FDA priority review for Leqembi Iqlik could transform Alzheimer’s drug initiation at home
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.
Pharma & Biotech
NeuroSense expands Alzheimer’s IP with U.S. patent, but all eyes are on RoAD trial results
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.